Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 801–892 of 892
Beyond procedural success after TAVI: is multi-pillar heart failure therapy the next frontier?
Stolte, T., Nestelberger, T., & Mahfoud, F. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag188
Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors
Ni, H., Piggott, S., Festa, M. C., Faruque, L. I., & Cherney, D. Z. I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2723583
“Finerenone was also associated with a significant reduction in cardiovascular mortality and HF events in T2D and preserved ejection fraction in the FINEARTS-HF trial [52].”
From risk marker to treatment trigger: biomarker-guided decision-making in acute heart failurePreprint
Sosnov, M., & Seleznova, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10629275/v1
Fan, A., Chen, X., Yang, K., Ma, X., Gao, H. T., Wang, B., Fan, G., & Li, L. (2026) · Biomolecules · doi:10.3390/biom16091241
“…or preserved ejection fraction, showing a reduction in worsening HF events and cardiovascular death, while the Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes (FINE-HEART) pooled analysis further supported benefit across a broad spectrum of HF phenotypes [174,175].”
Chabalout, M. N., Alazzeh, M., Othman, D., & Virk, J. P. S. (2026) · Cureus · doi:10.7759/cureus.115294
Ono, R., Docherty, K. F., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., Senni, M., Shah, S. J., Schou, M., Voors, A. A., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103297 · Cited by 1
Self-citationSeth, S., Chopra, V., Sinha, N., Nair, T., Böhm, M., Sawhney, J. P. S., Oomman, A., Jaswal, A., Gopi, A., Rao, S., et al. (2026) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_64_26
Self-citationAMERICCAASS Registry: A Contemporary View of Heart Failure in the Americas
Seni-Molina, S., Arango-Ibañez, J. P., Villegas‐Céspedes, V., Valencia, A., León-Giraldo, H., Borges, Y., Sánchen, E. S., Jiménez, M. V., Lugo-Peña, J. R., Ramírez, G. A. O., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047844
“47–49 Despite this positive impact, the implementation of GDMT remains suboptimal.”
Yan, Z., Pu, X., Ren, T., Cai, Y., Xu, Y., Chen, J., Chang, X., Wang, Y., Liu, Z., & Liu, R. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07941-z
Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
Cheng, C., Tang, M., 张兆波, Qu, R., Pei, J., Liu, T., Qu, S., You, S., Cui, S., Wang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77260 · Cited by 1
“Finerenone reduces heart failure events in HFpEF [ 164 ].”
Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure
Chimura, M., Pellicori, P., Docherty, K. F., Claggett, B. L., Campbell, R. T., Desai, A. S., Packer, M., Jhund, P. S., Petrie, M. C., Rouleau, J. L., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.013 · Cited by 1
Self-citationMehilli, J., Steffen, J., Rudolph, T. K., Haum, M., Giannini, C., Stark, K., Ince, H., Conradi, L., Joner, M., Schäfer, A., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.017 · Cited by 1
Ripoll, J. G., Herrera, H. R., Zaremba, S., Maruniak, S. R., Ursoleo, J. D., Wieruszewski, P. M., & Ramakrishna, H. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.08.160
Increasing plasma potassium and risk of atrial fibrillation: the POTCAST trial
Zheng, C., Winsløw, U., Danielsen, E. M., Sakthivel, T., Iversen, K. K., Bosselmann, H. S., Risum, N., Jøns, C., & Bundgaard, H. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag436
Lu, H. Y., Claggett, B. L., Ostrominski, J. W., Pfeffer, M. A., Pitt, B., Jhund, P. S., McMurray, J. J. V., Solomon, S. D., Desai, A. S., & Vaduganathan, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag245 · Cited by 2
Self-citationCardio-renal protection of MRAs in kidney-transplanted diabetic patients
Essawy, B. E., Safa, K., Dalbhi, S. A., & Chandraker, A. K. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108425 · Cited by 2
Voronkov, L. G., Долженко, М. М., Zharinov, O. J., Zaychenko, G. V., Кланца, А. І., Koval, O., Kravcheniuk, Y. Y., Лашкул, Д. А., Mishchenko, L. A., Parkhomenko, A. N., et al. (2026) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2026.4.7180
Self-citationWang, N., Claggett, B. L., Pfeffer, M. A., Ferreira, J. P., Zannad, F. M., Pitt, B., Packer, M., Docherty, K. F., McMurray, J. J. V., Solomon, S. D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04623-z
“From 2020 to 2023, the FINEARTS-HF trial randomly assigned 6,001 adults ≥40 years with symptomatic HF and an LVEF ≥ 40% to finerenone or matching placebo 36 .”
Self-citationHormonal Modulation in Chronic Coronary Syndrome: From Neurohormonal Activation to Endocrine Targets
Brie, A. D., Popescu, R., Mornoş, C., & Brie, D. M. (2026) · Biomedicines · doi:10.3390/biomedicines14091954
“…( n = 6001; ≈ 16% relative reduction, rate ratio 0.84), and lowered the primary kidney composite (hazard ratio 0.82) in type-2-diabetic chronic kidney disease in FIDELIO-DKD ( n = 5734)—populations that overlap closely with the aldosterone-rich, CKD-associated CCS phenotype defined here [65,66].”
InfluentialBasile, C., Monzo, L., Farmakis, D. T., Keramida, K., Liori, S., Kapelios, C. J., Sverdlov, A. L., Grupper, A., Ambrosy, A. P., & Canonico, M. E. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10675-7
Qamar, H., Saini, J. S., Figarska, S. M., Buys, E. S., & Wagh, V. (2026) · Cells · doi:10.3390/cells15171588
“[50,51].”
ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome
Bansal, N., Bjornstad, P., Bress, A. P., Chang, T. I., Cheng, X. S., Estrella, M. M., Go, A. S., Mottl, A. K., Navaneethan, S. D., Neuen, B. L., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001231 · Cited by 3
Ferrannini, G., Pol, T., Ljungman, C. E. A., Dahlström, U., Merolla, A., & Lund, L. H. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag249
Elsayed, A., Ayoub, W. J., ELSAYED, N., Stephens, J. P., Udongwo, N., Elsayed, Y. A.-E., & Ghali, J. K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00322-3
“Most recently, the FINEARTS-HF trial demonstrated that finerenone reduced worsening heart failure events and cardiovascular death in HFmrEF/HFpEF (HR 0.84; 95% CI 0.74–0.95) [28], establishing its role beyond diabetic kidney disease into the HFpEF domain where GLP-1RAs also demonstrate benefit.”
InfluentialAbomohsen, M., Alkuwaiti, M. A., Alghzawi, H. M., Hamed, B. M., Elkasaby, M. H., Rifai, M. K., Bakr, H. M., Idries, I. Y., Zepeda, I. A., & Ramasubbu, K. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001929 · Cited by 1
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
“FINEARTS-HF, published online on September 1, 2024, subsequently extended randomized clinical evidence for fi nerenone to patients with heart failure and mildly reduced or preserved ejection fraction (21, 24, 37, 98).”
Gembillo, G., Sessa, C., Zanoli, L., Visconti, L., Ricca, M. F., Cicero, L. L., Corsonello, A., Petrina, S. M., Nicosia, A., Soraci, L., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16090466 · Cited by 1
“…showed that finerenone raised the hazard of serum potassium > 5.5 mmol/L, approximately twofold relative to placebo [31], with potassium > 6.0 mmol/L in 3.0% versus 1.4%, confirming that hyperkalemia is an MR-antagonism class effect regardless of steroidal versus non-steroidal scaffold [31,32].”
InfluentialChattha, S. S., Kapadia, K., Lynch, D., & McWhorter, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1812235
“The non-steroidal agent finerenone, by contrast, significantly reduced the composite of cardiovascular death and total worsening heart failure events in HFmrEF and HFpEF in FINEARTS-HF, providing the first definitive evidence of benefit from this class across this ejection fraction range (76, 112).”
Decongestion in acute heart failure: A contemporary clinical review
Beukian, S., Shah, J., & Lotan, D. (2026) · Heart & Lung · doi:10.1016/j.hrtlng.2026.102944
Wärnberg, K., Haggård, C., Bergen, K., Falhammar, H., Mannheimer, B., & Lindmark, K. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag064
Discharge use of mineralocorticoid receptor antagonists and long-term outcomes in HFpEF
Morinaga, T., Natsuaki, M., Isotani, A., Kanenawa, K., Yamamoto, K., Fukunaga, M., Yajima, A., Hyodo, M., Shirai, S., Andò, K., et al. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.09.003
Matsuhiro, Y., Nakamura, D., Ide, S., Higashino, N., Sugae, H., Okuno, S., Kosugi, S., Kawamura, A., Maeda, K., Shimamura, K., et al. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70884
Zhou, Z., Fu, L., Chen, D., Yu, P., Xu, G., Wu, Q., Wu, T., & Yang, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71305
HFpEF in Asia—Clinical Characterization and Therapeutic Strategies
Tromp, J., Teng, T. K., Tay, W. T., Chandramouli, C., Schiattarella, G. G., & Lam, C. S. P. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.08.009
Self-citationDiagnostic challenges in primary aldosteronism evaluation and finerenone use
Xu, Y., Song, K., Wu, S., Li, J., & Pan, S. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06619-2
“To date, clinical studies of finerenone have mainly focused on populations with diabetic kidney disease, chronic kidney disease, and heart failure with preserved or mild reduced ejection fraction [12].”
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
Tsuda, K., Maeda, D., Kanzaki, Y., Sakane, K., Akamatsu, K., Sakatani, Y., Ito, T., Okuno, T., Kida, K., Enzan, N., et al. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.09.005
Yao, Y., Gu, Z., Hu, J., Zhu, W., & Lin, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108466
Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure
Ostrominski, J. W., Causland, F. R. M., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.3507
Self-citationCardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder
Shen, L., Abel, E. D., Arany, Z. P., Baur, J. A., Pei, L., & Suszták, K. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01127-4 · Cited by 1
Komori, T., Lauder, L., & Kario, K. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag273
Michos, E. D., Ambrosy, A. P., & Fonarow, G. C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103280
The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation
Fu, M., Savarese, G., & Swedberg, K. B. (2026) · Cardiology Plus · doi:10.1097/cp9.0000000000000177
Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
Gembillo, G., Calabrese, V., Soraci, L., Cicero, L. L., Scapellato, M., Messina, R., Ricca, M. F., Stancanelli, M. R., Corsonello, A., & Santoro, D. (2026) · Medicina · doi:10.3390/medicina62101855
“The benefit was observed in patients receiving and not receiving SGLT2 inhibitor therapy at baseline [58].”
Yao, Z., Xiao, J., Li, Y., Gao, X., Zhang, C., Zhang, Y., & Han, T. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100905
Ma, Q., Zhang, S., Guan, C., Liu, Y., Yang, X., Chen, X., Jin, S., & Xiao, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838338
Safety profile of finerenone: Pooled analysis of different types of arrhythmic events
Bazoukis, G., Clarke, E. V., & Tse, G. (2026) · Journal of Cardiology · doi:10.1016/j.jjcc.2026.09.008
Sánchez‐Bayuela, T., Barrera‐Chimal, J., & Jaisser, F. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01125-6 · Cited by 1
“Severe hyperkalaemia (potassium >6.0 mmol/l) occurred in ~3.0% of patients in the finerenone group versus ~1.4% of those in the placebo group 227 .”
Influential贾, 秋. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.55326
Shafi, T., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P. R., BRINKER, M. D., Rohwedder, K., Scott, C., Farag, Y. M. K., & Filippatos, G. S. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag299
Self-citationAlmeida-Alvarado, M. P., Solís, D. A. C., Mayorga, O. R. L., & Ávila, J. D. B. (2026) · Atlas Research Journal · doi:10.65305/arj.v4n1.2026.84
Ausiello, A., Lalaguna, L., López-Olañeta, M. M., Torroja, C., Palacios-Merino, J., Sánchez‐Cabezudo, C., Rivas, P., Villalba‐Orero, M., Fernandez-Cortes, E., García‐Pavía, P., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag193 · Cited by 1
Cardiovascular-Kidney-Metabolic Overlap in Patients Hospitalized for Heart Failure
Kittipibul, V., Ayodele, I., Fonarow, G. C., Alhanti, B., Spall, H. G. C. V., Pandey, A., Lewsey, S. C., & Greene, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.4215
Ha, P. T. K., Chao, C., Hung, C.-L., Chang, H.-Y., Chen, C.-W., Lin, Y., Huang, C.-Y., Shao, Y. J., & Hsu, C.-Y. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag246
“13 A recent individual patient-level meta-analysis of major MRA trials, including TOPCAT and FINEARTS-HF, showed that in HFmrEF/ HFpEF, MRA therapy reduced the composite of cardiovascular death or HF hospitalization (HR 0.87, 95% CI 0.79–0.95), with a clearer effect on HF hospitalization than on…”
Influential2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure
Chopra, V., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D., Burgos, L. M., Butler, J., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.09.001 · Cited by 1
Self-citationCei, F., Refaie, A. F. A., Dolenti, S., Campi, G., Cipollini, F., Borromei, C., Parolini, F., Panigada, G., Bulli, G., Filetti, S., et al. (2026) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2026.106443
Wang, H., Li, Y., Qin, C., Chen, X., Wang, K., Zhang, M., & Cheng, W. (2026) · iScience · doi:10.1016/j.isci.2026.117553 · Cited by 1
Walli-Attaei, M., Lund, L. H., Luengo-Fernández, R., Gray, A. M., Torbica, A., Huculeci, R., Aboyans, V., Timmis, A., Vardas, P. E., Maggioni, A. P., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag236
К.О., П. (2026) · Український медичний часопис · doi:10.32471/umj.1680-3051.281001
Engineering the geriatric heart to model HFpEF
Bass-Stringer, S., Lees, J. G., & Lim, S. Y. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10683-7
Marino, G., Fusco, S. A. D., Graziano, E., Corradetti, S., Aquilani, S., Fedele, S., Nardi, F., Gabrielli, D., Savoia, C., & Colivicchi, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197694
Al-Nusair, M., Haddad, T. A., Khurana, S., & Al‐Nusair, J. (2026) · Research Square · doi:10.21203/rs.3.rs-11263755/v1
Mauriello, A., Cetoretta, V., Giudice, C. D., Correra, A., Maratea, A. C., Gioia, R., Liccardo, B., Esposito, G., Russo, V., & D’Andrea, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102257
“…which enrolled patients with heart failure and mildly reduced or preserved ejection fraction (LVEF ≥ 40%), finerenone significantly reduced the composite of total worsening heart failure events and cardiovascular death compared with placebo (rate ratio 0.84, 95% CI 0.74–0.95; p = 0.007) [47].”
InfluentialEpelde, F. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1956165
“…death in patients with mildly reduced or preserved ejection fraction, providing an additional option particularly relevant to patients with mineralocorticoid-receptor activation, diabetes, kidney disease, or inflammatory-fibrotic features, while requiring potassium and renal monitoring (61).”
Nurse led titration of guideline-directed medical therapy for heart failure: an operative flow chart
Gori, M., Barisone, M., Maria, R. D., Fazzini, L., Spagnolin, M., Rizzello, V., Marchesi, M., Pini, D., Radini, D., D’Elia, E., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag223
“…as recently documented in the FINEARTS-HF trial, may provide additional benefit on mortality from cardiovascular cause and hospitalization for HF. 27 Although no randomized trial evidence supports RASI and β -blocker in patients with HFmrEF and HFpEF, data from the STRONG-HF and the Italian…”
InfluentialSelf-citationDiretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830 · Cited by 1
Diretriz Brasileira de Cardiogeriatria – 2026
Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795
Diaz, R., Ohlrogge, A. H., & Schutte, A. E. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag083
Gámez, M. A., Gonzalez-Manzanares, R., Bonilla‐Palomas, J. L., Esteban‐Fernández, A., Mayoral, A. R., Muñiz, J., Ruiz-Ortiz, M., Crespín-Crespín, M., Anguita-Sánchez, M., & Mesa-Rubio, D. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2026.107658
Sakata, Y., Matsuoka, Y., 後岡広太郎, Kyodo, A., Kohsaka, S., Obokata, M., Nagai, T., Anzai, T., Ohtani, T., Yoshio, Y., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0356
Therapie des Typ-2-Diabetes – Praxisempfehlung der DDG
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M., Siegel, E. G., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2866-0999
Zaidi, N. E., Azizan, E. A. B. A., & Ali, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102321
“Finerenone demonstrated significant reductions in composite renal and cardiovascular outcomes in FIDELIO-DKD [205], cardiovascular events in FIGARO-DKD [206] and worsening heart failure in FINEARTS-HF [207,208] at a magnitude exceeding blood pressure reduction alone.”
Ali, S. M., Ahmad, M., Khan, L., Jacqueline, K., O'Connor, N., Kukreja, N., Woo, A., Quadri, S. F. S., Ahmad, R. R., Ahmad, M. T., et al. (2026) · F1000Research · doi:10.12688/f1000research.181441.1
Aldosterone–mineralocorticoid receptor signaling and residual cardiorenal risk in type 2 diabetes
Zhao, S., Wang, C., & Ou, Y. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02811-4
Oh, H. E., & Hyun, J. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0076
“43,44) Finerenone thus shares the NT-proBNP-independent relative benefit pattern of ARNI and SGLT2i, distinguishing it from spironolactone in this respect.”
Aldosterone and residual cardiorenal risk: pathophysiology and emerging therapeutic strategies
Kanbay, M., AlShiab, R., Shah, E., Abdo, A., Ortíz, A., Mallamaci, F., & Zoccali, C. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag243
Park, H., Lee, N., & Park, S. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0064
“115,116) However, patients with active or recent malignancy were largely excluded from major HFpEF trials, limiting applicability of these agents to cancer patients.”
Xuzheng, Z., Xia, L., Li, L., & Tang, B. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1931636
“As core indicators for evaluating myocardial contractile function and cardiac pumping efficiency, elevated levels of LVEF and CO indicate enhanced myocardial contractility and improved overall cardiac pumping function (33).”
Zhang, D., Zhao, Y., Chen, H., & Miao, Y. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1984666
Shankara, S. B., Premananthan, S., Rajapreyar, I. N., & Sparks, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208130
“Current use is therefore extrapolated from the Class IIb recommendation for MRAs in the general HFpEF population, the TOP-CAT findings with spironolactone, and the FINEARTS-HF results with finerenone [46,47].”
Insuficiencia cardíaca: manejo perioperatorio
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(26)52197-2
PAH in the era of obesity: navigating phenotypes of pulmonary hypertension
Tager, D., Bernardo, R. J., & Tonelli, A. R. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2753850
Biostatistics with small effect size in the computerized age: the illusion of certainty?
Levinson, S. S. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107235
Interpreting Short-Term Safety and Albuminuria in the FINE-TURK Registry
Shang, J., Li, L., & Tan, L. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07979-z
Normuradov, A. U., Zhirov, I., & Tereshchenko, S. (2026) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20262103111
Diabetes mellitus im Alter – Praxisempfehlung der DDG
Zeyfang, A., Lee-Barkey, Y.-H., & Bahrmann, A. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2866-0305
Fernández‐Cisnal, A., Lorenzo, M., Palau, P., & Núñez, J. E. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107617
Riccardi, M., Savarese, G., Butler, J., Lombardi, C., Solomon, S. D., & Inciardi, R. M. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.10.002
Self-citationTriage in the Cardiometabolic Labyrinth
Dhont, S., & Trenson, S. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103210
Serpico, C., Luisi, E., Morello, M., Solimene, A., Granata, M., Acampora, B., Titolo, G., Bernazeaut, J., D’Elia, S., Loffredo, F. S., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16110557
Zhang, J., 王永健, Li, J., Chen, Y., Peng, X., Thabane, L., Lip, G. Y. H., & Li, G. (2026) · Drugs · doi:10.1007/s40265-026-02409-8
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.